 All of these drugs - vorinostat, bortezomib, lenalidomide and dexamethasone, are approved by the FDA U.S. Food and Drug Administration. They have not been approved in this combination for use in your type of cancer or any other type of cancer. Vorinostat is approved for treatment of patients with a different type of cancer Cutaneous T-Cell Lymphoma. Bortezomib is currently approved for the treatment of multiple myeloma. Lenalidomide is currently approved for the treatment of certain types of myelodysplastic syndrome another form of cancer affecting the blood and for use with dexamethasone for patients with multiple myeloma who have received at least one prior therapy. Dexamethasone is commonly used, either alone, or in combination with other drugs, to treat multiple myeloma. 